Periconceptional use of weight loss products including ephedra and the association with birth defects

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 82, Issue 8, 2008, Pages 553-562

  Bitsko, Rebecca H ^a,b   Reefhuis, Jennita ^a   Louik, Carol ^c   Werler, Martha ^c   Feldkamp, Marcia L ^d   Waller, D Kim ^e   Frias, Jaime ^a   Honein, Margaret A ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BOSTON UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Birth defects; Dieting; Ephedra; Pregnancy; Weight loss

Indexed keywords

EPHEDRINE;

ADULT; ANENCEPHALUS; AORTA STENOSIS; ARTICLE; BIRTH DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GREAT VESSELS TRANSPOSITION; HUMAN; INFANT; INFANT DISEASE; LIVE BIRTH; MAJOR CLINICAL STUDY; MOTHER; PRIORITY JOURNAL; RANDOMIZATION; SELF REPORT; WEIGHT REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; CASE-CONTROL STUDIES; CONGENITAL ABNORMALITIES; EPHEDRA; FEMALE; HUMANS; MOTHERS; PHYTOTHERAPY; PRECONCEPTION CARE; PREGNANCY; RISK FACTORS; SOCIAL CLASS;

EPHEDRA;

EID: 50249084351     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20472     Document Type: Article

References (65)

1. Anderson JL, Waller DK, Canfield MA, et al. 2005. Maternal obesity, gestational diabetes, and central nervous system birth defects. Epidemiology 16:87-92.
2. Becerra JE, Khoury MJ, Cordero JF, et al. 1990. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 85:1-9.
3. Blanck HM, Khan LK, Serdula MK. 2001. Use of nonprescription weight loss products: results from a multistate study. JAMA 286:930-935.
4. Blanck HM, Khan LK, Serdula MK. 2004a. Diet and physical activity behavior among users of prescription weight loss medications. Int J Behav Nutr Phys Act 1:17.
5. Blanck HM, Khan LK, Serdula MK. 2004b. Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Prev Med 39:1243-1248.
6. Blanck HM, Serdula MK, Gillespie C, et al. 2007. Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc 107:441-447.
7. Botto LD, Khoury MJ, Mulinare J, et al. 1996. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics 98:911-917.
8. Carmichael SL, Shaw GM, Schaffer DM, et al. 2003a. Dieting behaviors and risk of neural tube defects. Am J Epidemiol 158:1127-1131.
9. Carmichael SL, Shaw GM, Selvin S, et al. 2003b. Diet quality and risk of neural tube defects. Med Hypotheses 60:351-355.
10. Cedergren M, Kallen B. 2005. Maternal obesity and the risk for orofacial clefts in the offspring. Cleft Palate Craniofac J 42:367-371.
11. Cedergren MI, Kallen BA. 2003. Maternal obesity and infant heart defects. Obes Res 11:1065-1071.
12. Centers for Disease Control and Prevention. 2006. State-specific prevalence of obesity among adults - United States, 2005. Morb Mortal Wkly Rep 55:985-988.
13. Clark EB. 1996. Pathogenetic mechanisms of congenital cardiovascular malformations revisited. Semin Perinatol 20:465-472.
14. Cnattingius S, Bergstrom R, Lipworth L, et al. 1998. Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med 338:147-152.
15. Copp AJ, Greene ND, Murdoch JN. 2003. The genetic basis of mammalian neurulation. Nat Rev Genet 4:784-793.
16. Correa A, Botto L, Liu Y, et al. 2003. Do multivitamin supplements attenuate the risk for diabetes-associated birth defects? Pediatrics 111:1146-1151.
17. Creuzet SE, Martinez S, Le Douarin NM. 2006. The cephalic neural crest exerts a critical effect on forebrain and midbrain development. Proc Natl Acad Sci USA 103:14033-14038.
18. Czeizel AE, Toth M, Rockenbauer M. 1996. Population-based case control study of folic acid supplementation during pregnancy. Teratology 53:345-351.
19. Diet Pills with Ephedra. 2008 http://www.dietpills-with-ephedra.com/ (accessed 19 February 2008).
20. FDA. 2004. FDA Statement on Ephedra. http://www.fda.gov/bbs/topics/NEWS/ 2004/NEW01050.html (accessed 19 February 2008).
21. FDA. 2005. Phenylpropanolamine Information Page. http://www.fda.gov/cder/ drug/infopage/ppa/default.htm (accessed 19 February 2008).
22. FDA. 2006. FDA Requests Seizure of More Dietary Supplements Containing Ephedrine Alkaloids. http://www.fda.gov/bbs/topics/news/2006/NEW01297.html (accessed 19 February 2008).
23. Finer LB, Henshaw SK. 2006. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 38:90-96.
24. Gershwin M, German J, Keen C. 2000. Nutrition and Immunology - Principles and Practice. New Jersey: Humana Press.
25. Groenen PM, van Rooij IA, Peer PG, et al. 2004. Low maternal dietary intakes of iron, magnesium, and niacin are associated with spina bifida in the offspring. J Nutr 134:1516-1522.
26. Haller CA, Benowitz NL. 2000. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343:1833-1838.
27. Itikala PR, Watkins ML, Mulinare J, et al. 2001. Maternal multivitamin use and orofacial clefts in offspring. Teratology 63:79-86.
28. Johnson K, Posner SF, Biermann J, et al. 2006. Recommendations to improve preconception health and health care - United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recomm Rep 55:1-23.
29. Jones KL, Johnson KA, Dick LM, et al. 2002. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. Teratology 65:125-130.
30. Kimmons JE, Blanck HM, Tohill BC, et al. 2006. Multivitamin use in relation to self-reported body mass index and weight loss attempts. MedGenMed 8:3.
31. Kontogianni M, Zampelas A, Tsigos C. 2006. Nutrition and inflammatory load. Ann NY Acad Sci 1083:214-238.
32. Kouba S, Hallstrom T, Lindholm C, et al. 2005. Pregnancy and neonatal outcomes in women with eating disorders. Obstet Gynecol 105:255-260.
33. Krapels IP, Rooij IA, Wevers RA, et al. 2004a. Myo-inositol, glucose and zinc status as risk factors for non-syndromic cleft lip with or without cleft palate in offspring: a case-control study. BJOG 111:661-668.
34. Krapels IP, van Rooij IA, Ocke MC, et al. 2004b. Maternal dietary B vitamin intake, other than folate, and the association with orofacial cleft in the offspring. Eur J Nutr 43:7-14.
35. Maglione M, Miotto K, Iguchi M, et al. 2005. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events. Am J Psychiatry 162:189-191.
36. Mitchell LE, Murray JC, O'Brien S, et al. 2003. Retinoic acid receptor alpha gene variants, multivitamin use, and liver intake as risk factors for oral clefts: a population-based case-control study in Denmark, 1991-1994. Am J Epidemiol 158:69-76.
37. MRC Vitamin Study Research Group. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338:131-137.
38. Naggan L. 1972. The epidemiology of neural tube defects. Isr J Med Sci 8:549-555.
39. National Institutes of Health, US Department of Health and Human Services. 1998. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. Bethesda, MD.
40. Pittler MH, Schmidt K, Ernst E. 2005. Adverse events of herbal food supplements for body weight reduction: systematic review. Obes Rev 6:93-111.
41. Rasmussen SA, Olney RS, Holmes LB, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67:193-201.
42. Robert E, Francannet C, Shaw G. 1995. Neural tube defects and maternal weight reduction in early pregnancy. Reprod Toxicol 9:57-59.
43. Samenuk D, Link MS, Homoud MK, et al. 2002. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 77:12-16.
44. Shaw GM, Carmichael SL, Laurent C, et al. 2006. Maternal nutrient intakes and risk of orofacial clefts. Epidemiology 17:285-291.
45. Shaw GM, Todoroff K, Carmichael SL, et al. 2001. Lowered weight gain during pregnancy and risk of neural tube defects among offspring. Int J Epidemiol 30:60-65.
46. Shaw GM, Velie EM, Schaffer D. 1996. Risk of neural tube defect-affected pregnancies among obese women. JAMA 275:1093-1096.
47. Shekelle PG, Hardy ML, Morton SC, et al. 2003. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 289:1537-1545.
48. Simic S, Idrizbegovic S, Jaganjac N, et al. 1995. Nutritional Effects of the Siege on New-born Babies in Sarajevo. Eur J Clin Nutr 49 Suppl 2:S33-36.
49. Smithells RW, Sheppard S, Schorah CJ, et al. 1980. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1:339-340.
50. Stevenson R. 2006. Human Malformations and Related Anomalies. Human Malformations and Related Anomalies. New York: Oxford University Press.
51. The American College of Obstetricians and Gynecologists. 2007. Good health before pregnancy. Preconception care. Washington, DC.
52. Theobald HE. 2007. Eating for pregnancy and breast-feeding. J Fam Health Care 17:45-49.
53. Torfs CP, Katz EA, Bateson TF, et al. 1996. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 54:84-92.
54. Vial T, Robert E, Carlier P, et al. 1992. First-trimester in utero exposure to anorectics: A French collaborative study with special reference to dexfenfluramine. Int J Risk Saf Med 3:207-214.
55. Waller DK, Mills JL, Simpson JL, et al. 1994. Are obese women at higher risk for producing malformed offspring? Am J Obstet Gynecol 170:541-548.
56. Waller DK, Shaw GM, Rasmussen SA, et al. 2007. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 161:745-750.
57. Watkins ML, Rasmussen SA, Honein MA, et al. 2003. Maternal obesity and risk for birth defects. Pediatrics 111:1152-1158.
58. Watkins ML, Scanlon KS, Mulinare J, et al. 1996. Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology 7:507-512.
59. Werler MM. 2006. Teratogen update: pseudoephedrine. Birth Defects Res A Clin Mol Teratol 76:445-452.
60. Werler MM, Louik C, Shapiro S, et al. 1996. Prepregnant weight in relation to risk of neural tube defects. JAMA 275:1089-1092.
61. Werler MM, Pober BR, Nelson K, et al. 1989. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 129:415-421.
62. Werler MM, Sheehan JE, Mitchell AA. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 155:26-31.
63. Wernosky G. 2001. Transposition of the great arteries. In: Allen HD, Clark EB, editors. Moss and Adams' Heart diseases in infants, children, and adolescents including the fetus and young adult. 6th ed. Philadelphia: Lippincott and Williams. p 1027-1101.
64. Wynn A, Wynn M. 1993. The effects of food shortage on human reproduction. Nutr Health 9:43-52.
65. Yoon PW, Rasmussen SA, Lynberg MC, et al. 2001. The National Birth Defects Prevention Study. Public Health Reports 116:32-40.